ArticleActa neurochirurgica2025
Gamma Knife radiosurgery for brain arteriovenous malformations - a single-center experience.
Article in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGamma Knife stereotactic radiosurgery (SRS) has emerged as a non-invasive and effective treatment for brain arteriovenous malformations (AVM), particularly in cases where surgical resection is not feasible. The factors influencing AVM obliteration following Gamma Knife radiosurgery remain incompletely understood and differing results across studies indicate the need for further research. This study reviews a single center's 20-year experience with Gamma Knife radiosurgery for AVMs, evaluating factors associated with successful treatment outcomes.
methodsA retrospective analysis was conducted on 241 patients treated with Gamma Knife SRS for intracranial AVMs at University Hospital Center Zagreb between 2004 and 2021. Patient demographics, AVM characteristics, prior treatments, radiosurgical parameters, and clinical outcomes were analyzed. AVM obliteration was assessed using MR angiography and digital subtraction angiography. Binary logistic regression and Cox regression analysis were performed to identify factors associated with treatment success and shorter time to obliteration.
resultsAVM obliteration was achieved in 171 patients (71%), with a mean time to complete obliteration of 3 years. Higher prescription doses correlated with increased obliteration rates (p < 0.05), as did hemispheric AVM location (p < 0.05) while smaller nidus volumes were associated with faster obliteration times (p < 0.05). 75.5% of previously embolized AVMs achieved obliteration vs 68.2% of non-embolized AVMs, however the difference was not statistically significant. The introduction of cone beam CT angiography in treatment planning improved obliteration rates (69.1% to 75.8%), though statistical significance was not reached. The overall complication rate was 15.4%, with 5.8% experiencing post-SRS hemorrhage.
conclusionHigher prescription doses correlated with improved obliteration rates, and smaller AVMs achieved faster obliteration. The use of additional imaging modalities in treatment planning possibly contributed to non-inferior obliteration rates in previously embolized AVMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.